miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy

Molecular and Cellular Endocrinology

Volumn 433, Issue , 2016, Pages 75-86

  Sun, Yan ^a   Peng, Rui ^a   Peng, Huimin ^a   Liu, Handeng ^a   Wen, Li ^a   Wu, Tianhui ^a   Yi, Hong ^a   Li, Ailing ^a   Zhang, Zheng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Inflammation; LMP7; MiR 451; NF B

Indexed keywords

ALBUMIN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LARGE MULTIFUNCTIONAL PROTEASE 7; MICRORNA; MICRORNA 451; PROTEINASE; UNCLASSIFIED DRUG; LMP7 PROTEIN; MIRN451 MICRORNA, MOUSE; PROTEASOME;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DB/DB MOUSE; DIABETIC NEPHROPATHY; DOWN REGULATION; GENE EXPRESSION; GENE SEQUENCE; GLOMERULOPATHY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN SITU HYBRIDIZATION; INFLAMMATION; KIDNEY; KIDNEY CORTEX; LMP7 GENE; LUCIFERASE ASSAY; MALE; MESANGIUM CELL; MICROALBUMINURIA; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; WESTERN BLOTTING; ANIMAL; CELL LINE; EXPERIMENTAL DIABETES MELLITUS; GENETIC TRANSCRIPTION; GLOMERULUS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DOWN-REGULATION; GLUCOSE; INFLAMMATION; KIDNEY; KIDNEY GLOMERULUS; MALE; MESANGIAL CELLS; MICE; MICRORNAS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84973352732     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2016.06.004     Document Type: Article

References (51)

1. Akiyama K., Kagawa S., Tamura T., Shimbara N., Takashina M., Kristensen P., Hendil K.B., Tanaka K., Ichihara A. Replacement of proteasome subunits X and Y by LMP7 and LMP2 induced by interferon-gamma for acquirement of the functional diversity responsible for antigen processing. FEBS Lett. 1994, 343:85-88.
2. Araki S., Haneda M., Koya D., Sugimoto T., Isshiki K., Chin-Kanasaki M., Uzu T., Kashiwagi A. Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. Diabetologia 2007, 50:867-873.
3. Baker R.G., Hayden M.S., Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab. 2011, 13:11-22.
4. Bandres E., Bitarte N., Arias F., Agorreta J., Fortes P., Agirre X., Zarate R., Diaz-Gonzalez J.A., Ramirez N., Sola J.J., Jimenez P., Rodriguez J., Garcia-Foncillas J. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin. Cancer Res. 2009, 15:2281-2290.
5. Basler M., Mundt S., Muchamuel T., Moll C., Jiang J., Groettrup M., Kirk C.J. Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol. Med. 2014, 6:226-238.
6. Boldin M.P., Baltimore D. MicroRNAs, new effectors and regulators of NF-kappaB. Immunol. Rev. 2012, 246:205-220.
7. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
8. Castellano G., Cafiero C., Divella C., Sallustio F., Gigante M., Pontrelli P., De Palma G., Rossini M., Grandaliano G., Gesualdo L. Local synthesis of interferon-alpha in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis Res. Ther. 2015, 17:72.
9. Coppo R., Camilla R., Alfarano A., Balegno S., Mancuso D., Peruzzi L., Amore A., Dal Canton A., Sepe V., Tovo P. Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int. 2009, 75:536-541.
10. Donate-Correa J., Martin-Nunez E., Muros-de-Fuentes M., Mora-Fernandez C., Navarro-Gonzalez J.F. Inflammatory cytokines in diabetic nephropathy. J. Diabetes Res. 2015, 2015:948417.
11. Elsherbiny N.M., Abd El Galil K.H., Gabr M.M., Al-Gayyar M.M., Eissa L.A., El-Shishtawy M.M. Reno-protective effect of NECA in diabetic nephropathy: implication of IL-18 and ICAM-1. Eur. Cytokine Netw. 2012, 23:78-86.
12. Feuerhake F., Kutok J.L., Monti S., Chen W., LaCasce A.S., Cattoretti G., Kurtin P., Pinkus G.S., de Leval L., Harris N.L., Savage K.J., Neuberg D., Habermann T.M., Dalla-Favera R., Golub T.R., Aster J.C., Shipp M.A. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005, 106:1392-1399.
13. Ghosh S., Rodrigues B. Cardiac cell death in early diabetes and its modulation by dietary fatty acids. Biochim. Biophys. Acta 2006, 1761:1148-1162.
14. Himmelfarb J., Tuttle K.R. New therapies for diabetic kidney disease. N. Engl. J. Med. 2013, 369:2549-2550.
15. Inoue T., Takenaka T., Hayashi M., Monkawa T., Yoshino J., Shimoda K., Neilson E.G., Suzuki H., Okada H. Fibroblast expression of an IkappaB dominant-negative transgene attenuates renal fibrosis. J. Am. Soc. Nephrol. 2010, 21:2047-2052.
16. Kaur H., Chien A., Jialal I. Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol 2012, 303:F1145-F1150.
17. Kim S.W., Ramasamy K., Bouamar H., Lin A.P., Jiang D., Aguiar R.C. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7865-7870.
18. Kozomara A., Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014, 42:D68-D73.
19. Kuwabara Y., Horie T., Baba O., Watanabe S., Nishiga M., Usami S., Izuhara M., Nakao T., Nishino T., Otsu K., Kita T., Kimura T., Ono K. MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway. Circ. Res. 2015, 116:279-288.
20. Langmead B., Trapnell C., Pop M., Salzberg S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009, 10:R25.
21. Lim A.K., Tesch G.H. Inflammation in diabetic nephropathy. Mediat. Inflamm. 2012, 2012:146154.
22. Lu Y., Ahmed S., Harari F., Vahter M. Impact of Ficoll density gradient centrifugation on major and trace element concentrations in erythrocytes and blood plasma. J. Trace Elem. Med. Biol. 2015, 29:249-254.
23. Lv G., Hu Z., Tie Y., Du J., Fu H., Gao X., Zheng X. MicroRNA-451 regulates activating transcription factor 2 expression and inhibits liver cancer cell migration. Oncol. Rep. 2014, 32:1021-1028.
24. Makino H., Miyamoto Y., Sawai K., Mori K., Mukoyama M., Nakao K., Yoshimasa Y., Suga S. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006, 55:2747-2756.
25. Matoba K., Kawanami D., Okada R., Tsukamoto M., Kinoshita J., Ito T., Ishizawa S., Kanazawa Y., Yokota T., Murai N., Matsufuji S., Takahashi-Fujigasaki J., Utsunomiya K. Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1alpha. Kidney Int. 2013, 84:545-554.
26. McClelland A., Hagiwara S., Kantharidis P. Where are we in diabetic nephropathy: microRNAs and biomarkers?. Curr. Opin. Nephrol. Hypertens. 2014, 23:80-86.
27. Mogensen C.E., Christensen C.K., Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983, 32(Suppl. 2):64-78.
28. Moriwaki Y., Yamamoto T., Shibutani Y., Aoki E., Tsutsumi Z., Takahashi S., Okamura H., Koga M., Fukuchi M., Hada T. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003, 52:605-608.
29. Muchamuel T., Basler M., Aujay M.A., Suzuki E., Kalim K.W., Lauer C., Sylvain C., Ring E.R., Shields J., Jiang J., Shwonek P., Parlati F., Demo S.D., Bennett M.K., Kirk C.J., Groettrup M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 2009, 15:781-787.
30. Murata K., Yoshitomi H., Furu M., Ishikawa M., Shibuya H., Ito H., Matsuda S. MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK. Arthritis Rheumatol. 2014, 66:549-559.
31. Nesca V., Guay C., Jacovetti C., Menoud V., Peyot M.L., Laybutt D.R., Prentki M., Regazzi R. Identification of particular groups of microRNAs that positively or negatively impact on beta cell function in obese models of type 2 diabetes. Diabetologia 2013, 56:2203-2212.
32. Ostrowska H., Kruszewski K., Kasacka I. Immuno-proteasome subunit LMP7 is up-regulated in the ischemic kidney in an experimental model of renovascular hypertension. Int. J. Biochem. Cell. Biol. 2006, 38:1778-1785.
33. Redova M., Poprach A., Nekvindova J., Iliev R., Radova L., Lakomy R., Svoboda M., Vyzula R., Slaby O. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med. 2012, 10:55.
34. Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26:139-140.
35. Sakai N., Wada T. Revisiting inflammation in diabetic nephropathy: the role of the Nlrp3 inflammasome in glomerular resident cells. Kidney Int. 2015, 87:12-14.
36. Schmidt N., Gonzalez E., Visekruna A., Kuhl A.A., Loddenkemper C., Mollenkopf H., Kaufmann S.H., Steinhoff U., Joeris T. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 2010, 59:896-906.
37. Shultz P.J., DiCorleto P.E., Silver B.J., Abboud H.E. Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am. J. Physiol. 1988, 255:F674-F684.
38. Sun L., Kanwar Y.S. Relevance of TNF-alpha in the context of other inflammatory cytokines in the progression of diabetic nephropathy. Kidney Int. 2015, 88:662-665.
39. Uzu T., Yokoyama H., Itoh H., Koya D., Nakagawa A., Nishizawa M., Maegawa H., Yokomaku Y., Araki S., Abiko A., Haneda M. Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol. Clin. Exp. Nephrol. 2011, 15:58-63.
40. Visekruna A., Joeris T., Seidel D., Kroesen A., Loddenkemper C., Zeitz M., Kaufmann S.H., Schmidt-Ullrich R., Steinhoff U. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J. Clin. Investig. 2006, 116:3195-3203.
41. Wada J., Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin. Sci. Lond. 2013, 124:139-152.
42. Wang R., Wang Z.X., Yang J.S., Pan X., De W., Chen L.B. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011, 30:2644-2658.
43. Wang W., Shi Q., Guo T., Yang Z., Jia Z., Chen P., Zhou C. PDX1 and ISL1 differentially coordinate with epigenetic modifications to regulate insulin gene expression in varied glucose concentrations. Mol. Cell. Endocrinol. 2016, 428:38-48.
44. Wu C., Lv C., Chen F., Ma X., Shao Y., Wang Q. The function of miR-199a-5p/Klotho regulating TLR4/NF-kappaB p65/NGAL pathways in rat mesangial cells cultured with high glucose and the mechanism. Mol. Cell. Endocrinol. 2015, 417:84-93.
45. Yi B., Hu X., Zhang H., Huang J., Liu J., Hu J., Li W., Huang L. Nuclear NF-kappaB p65 in peripheral blood mononuclear cells correlates with urinary MCP-1, RANTES and the severity of type 2 diabetic nephropathy. PLoS One 2014, 9:e99633.
46. Yin P., Peng R., Peng H., Yao L., Sun Y., Wen L., Wu T., Zhou J., Zhang Z. MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells. Mol. Biotechnol. 2015, 57:1-11.
47. Yiu W.H., Lin M., Tang S.C. Toll-like receptor activation: from renal inflammation to fibrosis. Kidney Int. Suppl. 2014, 4(2011):20-25.
48. Zhang Z., Peng H., Chen J., Chen X., Han F., Xu X., He X., Yan N. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 2009, 583:2009-2014.
49. Zhang X., Wang X., Zhu H., Zhu C., Wang Y., Pu W.T., Jegga A.G., Fan G.C. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J. Mol. Cell. Cardiol. 2010, 49:841-850.
50. Zhang Z., Luo X., Ding S., Chen J., Chen T., Chen X., Zha H., Yao L., He X., Peng H. MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy. FEBS Lett. 2012, 586:20-26.
51. Zhong X., Chung A.C., Chen H.Y., Dong Y., Meng X.M., Li R., Yang W., Hou F.F., Lan H.Y. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013, 56:663-674.